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Structural Basis for Interactions between Tenascins
and Lectican C-Type Lectin Domains:
Evidence for a Crosslinking Role for Tenascins
trolling ECM assembly, particularly at a structural level,
is critical for understanding ECM turnover and homeo-
stasis under normal as well as pathological conditions.
Little is currently known about these interactions, and
very limited structural information is available at present
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Sweden The individual components of the ECM are produced
locally and secreted into the environment, where they2 Section for Connective Tissue Biology
3 Section for Molecular Pathology spontaneously assemble into well-organized networks
with different properties. One such network of criticalDepartment of Cell and Molecular Biology
Lund University importance for tissue function involves the ubiquitous
aggregating proteoglycans aggrecan, versican, neuro-BMC-C12
S-221 84 Lund can, and brevican, collectively known as lecticans
(Ruoslahti, 1996) or hyalectans (Iozzo and Murdoch,Sweden
1996). Aggrecan, the most extensively studied lectican,
is fundamental for cartilage function (Heinega˚rd and
Oldberg, 1989). The in vivo importance of lecticans isSummary
emphasized by findings from several mutant mouse
strains. Mutations in the aggrecan gene in the cmdThe C-terminal G3 domains of lecticans mediate
crosslinking to diverse extracellular matrix (ECM) pro- mouse strain lead to a drastically truncated aggrecan
protein which is neither processed in the endoplasmaticteins during ECM assembly, through their C-type lectin
(CLD) subdomains. The structure of the rat aggrecan reticulum nor secreted (Watanabe et al., 1994). This re-
sults in a functional null phenotype with disproportion-CLD in a Ca2-dependent complex with fibronectin
type III repeats 3–5 of rat tenascin-R provides detailed ate dwarfism and perinatal death. Furthermore, disrup-
tion of the versican gene in the hdf mouse strain leadssupport for such crosslinking. The CLD loops bind
Ca2 like other CLDs, but no carbohydrate binding is to heart malformation and death at the embryonic stage
(Mjaatvedt et al., 1998; Yamamura et al., 1997). Geneobserved or possible. This is thus the first example of
a direct Ca2-dependent protein-protein interaction of targeting of the neurocan (Zhou et al., 2001) and brevi-
can (Brakebusch et al., 2002) genes leads to impaireda CLD. Surprisingly, tenascin-R does not coordinate
the Ca2 ions directly. Electron microscopy confirms hippocampal long-term potentiation.
The lectican core proteins have an N-terminal globularthat full-length tenascin-R and tenascin-C crosslink
hyaluronan-aggrecan complexes. The results are sig- G1 domain, a central elongated domain of varying length
carrying glycosaminoglycan chains, and a C-terminalnificant for the binding of all lectican CLDs to tenas-
cin-R and tenascin-C. Comparison of the protein inter- globular G3 domain, as shown in Figure 1A (Heinega˚rd
and Oldberg, 1989). Both the G1 and G3 domains medi-action surface with that of P-selectin in complex with
the PGSL-1 peptide suggests that direct protein-pro- ate ECM interactions. The G1 domains bind hyaluronan
in interactions stabilized by the hyaluronan- and G1tein interactions of Ca2-binding CLDs may be more
widespread than previously appreciated. binding link proteins. The G3 domains are composed of
EGF repeats followed by a C-type lectin domain (CLD),
and then a short consensus repeat (SCR), and mediateIntroduction
binding to various ECM proteins, including tenascin-R
and tenascin-C.The extracellular matrix (ECM) provides the structural
and biomechanical properties crucial for tissue function. The tenascins are a family of large oligomeric glyco-
proteins with five known members: tenascin-C, tenas-ECM interactions and signals transmitted via cellular
cin-R, tenascin-X, -Y, and -W (Jones and Jones, 2000).receptors control many aspects of cellular life, for in-
They have an N terminus characterized by a series ofstance proliferation, differentiation, maintenance of dif-
cysteines and heptad repeats, a number of EGF-likeferentiation state, and survival (Giancotti and Ruoslahti,
repeats followed by fibronectin type III repeats (FnIII),1999). The ECM is continuously modified by the resident
some of which are alternatively spliced, and a fibrino-cells and adapts to changes in the environment (Aumail-
gen-like globular C-terminal domain (Figure 1B). Tenas-ley and Gayraud, 1998; Streuli, 1999). In diseases such
cin-R and -C form characteristic trimeric and hexamericas osteoarthritis and atherosclerosis, the balance be-
(hexabrachion) structures, respectively, through associ-tween ECM synthesis and degradation is disturbed. Un-
ation of their N-terminal domains (Figure 1B). Both ten-derstanding the molecular basis for the interactions con-
ascin-R and tenascin-C are expressed in the central
nervous system (CNS), and tenascin-C is also expressed
*Correspondence: derek.logan@mbfys.lu.se
in connective tissues during development. Tenascin-C4 Present address: Section for Molecular Pathology, Department of
is reexpressed in the adult, e.g., during wound healing,Cell and Molecular Biology, Lund University, BMC-C12, S-221 84
Lund, Sweden. and in vascular disease and tumorigenesis. Tenascin-R
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mains with ECM glycoprotein ligands are Ca2-depen-
dent, but contrary to expectation for CLDs, they are
independent of glycosylation (Aspberg et al., 1997). The
lectican binding sites on tenascin-R and tenascin-C are
located in FnIII repeats 3–5 (Day et al., 2004; Rauch et
al., 1997), whereas the binding to fibulin-1 (Aspberg et
al., 1999), fibulin-2 (Olin et al., 2001), and fibrillin-1 (Isogai
et al., 2002) is directed toward Ca2binding EGF repeats.
Thus, the lectican CLDs make a remarkably diverse set
of Ca2-dependent interactions with three distinctly dif-
ferent types of ligands: carbohydrates in sulfated glyco-
lipids (Miura et al., 1999), FnIII repeats in tenascins, and
EGF repeats in fibulins and fibrillin. All the protein ligands
are dimeric or multimeric and are believed to organize
the nascent lectican aggregates in the ECM, as outlined
in Figure 1C for tenascin-R. This has been directly visual-
ized in vitro for fibulin-2 (Olin et al., 2001).
The concept of multimeric tenascins functioning as
molecular crosslinkers between lectican-hyaluronan
complexes is corroborated by the disorganization of the
perineuronal nets observed in tenascin-R knockout mice
(Bruckner et al., 2000). Nevertheless, further structural
and functional evidence is required to support the notion
of in vivo crosslinking of lectican networks via the G3
domain. Detailed insight is given by the crystal structure
of the complex between the CLD of rat aggrecan and
FnIII repeats 3–5 (TN3–5) from rat tenascin-R presented
here. The structure represents a general model for the
interaction of lecticans with tenascin-R and -C and is
additionally the first structural study of a direct protein-
protein interaction of a Ca2 binding CLD—as opposed
to the well-known non-Ca2 binding C-type lectin-like
domains (CTLDs) from the immune system. The crystal
structure is supported by electron microscopy studies
showing the formation of networks between the full-
length molecules in vitro. The complex structure sug-
gests the existence of a conserved protein interaction
surface on the lectican CLDs corresponding to the pep-
tide binding surface of P-selectin in complex with theFigure 1. Schematic Diagram of Lecticans and Tenascins
N-terminal glycosulfopeptide of PSGL-1, implying that(A) The lecticans have a domain organization with N-terminal (G1)
direct protein-protein interactions of Ca2 binding CLDsand C-terminal (G3) globular domains. In aggrecan, which is shown
here, an additional G2 domain is inserted. The central part of the may be more common than previously appreciated.
molecule carries keratin sulfate (KS) and chondroitin sulfate (CS)
chains. Both G1 and G3 domains mediate interactions with other
ResultsECM components: G1 binds hyaluronan in an interaction stabilized
by the link proteins, and the G3 domain binds multimeric ECM pro-
teins such as tenascin-R. Overall Structure
(B) Tenascin-R and tenascin-C consist of an N-terminal multimeriza- The crystal structure of the complex between the CLD
tion domain followed by EGF-like repeats (diamonds), fibronectin
of rat aggrecan and FnIII repeats 3–5 of rat tenascin-Rtype III repeats (ovals), and a C-terminal fibrinogen-like globule
(TN3–5) was solved using three heavy-atom derivatives(hexagon). Additional FnIII repeats can be inserted through alterna-
and refined at a resolution of 2.6 A˚ (Table 1; Figure 2),tive splicing (shaded ovals). The lectican G3 CLD binding site has
been mapped to FnIII repeats 3–5 (black ovals). Tenascin-R forms with good geometry (Table 1). TN3 and TN4 are well
trimeric and tenascin-C hexameric structures (right part of panel). ordered, while the electron density for TN5 indicates
(C) Schematic of lectican ECM organization through interactions somewhat more disorder at the end furthest from the
with hyaluronan, link protein, and tenascin-R. The components are
CLD interaction area. However, this does not affect thedrawn as in (A).
interpretation of the interaction, which involves only
the well-ordered end of TN5 proximal to TN4.
has neuronal receptors and colocalizes with lecticans
and hyaluronan in specialized ECM structures known Tenascin-R
TN3–5 consists of 271 amino acids, with overall dimen-as perineuronal nets (Yamaguchi, 2000). Gene targeting
of either tenascin-C or -R resulted in neuronal abnormal- sions 118  39  38 A˚. The individual repeats have a
standard structure for FnIII repeats, consisting of a ities (Joester and Faissner, 2001).
The high-affinity interactions of the lectican G3 do- sandwich with strands A, B, and E on the top face and
Structure of an Aggrecan CLD-Tenascin-R Complex
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Table 1. Summary of Crystallographic Analysis
Data Set Native AuCN HoCl3 PtCl4
Concentration (mM) 20 10 10
Soaking time (min) 15 35 15
Wavelength (A˚) 1.097 1.008 1.035 1.097
Resolution (A˚) 2.6 2.9 3.1 3.5
Unique reflections 18,391 12,872 10,616 7,079
Overall completeness (%) 97.3 98.7 98.2 91.0
Anomalous completeness (%) – 99.3 94.4 –
Multiplicity 8.7 (6.1) 6.5 (6.0) 4.2 (4.2) 2.7 (2.5)
Rmerge (%) 0.072 0.079 0.113 0.100
Riso (%) 0.177 0.274 0.243
Ranom (%) — 0.035 0.074 —
No. of heavy atom sites 1 1 2
Rcullis: iso/anoma (%) —/— 0.87/0.95 0.92/0.94 0.96/—
Phasing power: iso/anoma —/— 0.75/0.55 0.47/0.18 0.45/—
Rcryst/Rfree (%) 21.0/23.7
Rmsd bonds/angles (A˚/) 0.014/1.4
No. of non-H atoms 3209
Ramachandran plot quality (%)
Most favored 86.6
Additional allowed 12.8
Generously allowed 0.6
Disallowed 0.0
Numbers in parentheses represent the highest resolution shell (2.67–2.60 A˚).
Rmerge  hi|Ii(h)  I(h)	|/hiIi(h), where i are the independent observations of reflection h.
Rcullis  h(||FPH(h)  FP(h)|  FHcalc(h))|/h|FPH(h)  FP(h)|.
Rcryst  h|Fobs(h)  Fcalc(h)|/hFobs(h).
a To 2.9 A˚.
strands C, C
, F, and G on the bottom. The tilt and twist However, no reducing agents were used in the purifica-
tion and crystallization. In any case, the surroundingsangles defining the relative orientations of each pair of
consecutive repeats (Bork et al., 1996), as well as the are indistinguishable from a Ca2-free aggrecan CLD
structure with a fully formed 99:115 disulfide (A.L., A.I.O.,solvent-accessible areas buried in the interaction sur-
faces, are listed in Table 2. TN3–5 has an extended confor- A.A., and D.T.L., unpublished results). Additionally, the
partial reduction has no effect on the Ca2 coordination,mation, reflected in the tilt angles, which are very similar
to published values for FnIII repeats 8–10 (Leahy et al., judging by comparison to the other CLD structures. Par-
tial reduction of a disulfide has been observed in man-1996) and 12–14 (Sharma et al., 1999) of fibronectin.
Binding of the aggrecan CLD thus does not induce sig- nose binding protein A (MBP-A) (Burling et al., 1996).
The aggrecan-tenascin interaction is highly Ca2 de-nificant bending of TN3–5. There is more variation in the
twist angles (see Discussion). pendent (Aspberg et al., 1995, 1997). Three Ca2 ions
are found in the structure, all of which are in aggrecan
and coordinated as expected for CLDs (Figure 3D). FiveThe Aggrecan CLD
Together with the CLDs of the other lecticans brevican, amino acids (Gln88, Asp90, Glu97, Asn111, and Asp112)
and one water molecule coordinate Ca2, which is theneurocan, and versican, the aggrecan CLD forms group
I of the C-type lectin family (Day, 1994). The overall carbohydrate binding or “principal” Ca2 ion in many
CLDs. The coordination is pentagonal bipyramidal withstructure is highly canonical for this family (Figure 3).
Aggrecan contains a long-form CLD (126 residues) with seven ligands, as Asp112 contributes two oxygen atoms
(carbonyl oxygen and O1). Five amino acids (Asp64,three disulfide bridges (Figures 3A and 3C), like, e.g.,
tetranectin (Kastrup et al., 1998) and asialoglycoprotein Glu68, Asn91, Glu97, and Asp98) coordinate Ca1, where
Glu97 coordinates Ca2 with its O2 and Ca1 with itsreceptor H1 subunit (ASPGR) (Meier et al., 2000). A
search using the DALI server (Holm and Sander, 1993) carbonyl oxygen. The Ca1 coordination geometry is hex-
agonal bipyramidal with eight ligands, as Asp64 andrevealed strong similarity to a variety of other Ca2 bind-
ing and non-Ca2 binding CTLDs, including lithostatine Glu68 are both bidentate. Ca3 is more loosely bound to
the protein, being coordinated by three oxygen atoms(Bertrand et al., 1996), mannose binding protein MBP
(Weis et al., 1991), and E-selectin (Somers et al., 2000). from the protein and four water molecules. The geometry
is pentagonal bipyramidal with seven ligands, whereNot surprisingly, the lowest overall rms deviation (0.76 A˚
for 114 amino acids) was found for the long-form CLD Asp98 is bidentate (O1 and O2). Glu68, which also
coordinates Ca1, contributes its O1. Ca2 is conservedof ASGPR.
Two of the disulfide bridges, between cysteines 3:14 in all structurally characterized CLDs, but the presence
of Ca1 and Ca3 is more variable. Ca3 was first observedand 31:123, have unambiguous electron density. The
third disulfide, Cys99:Cys115, is approximately 8 A˚ from in the crystal structure of MBP in complex with an oligo-
saccharide (Weis et al., 1992), and it was believed thatCa2. The electron density suggests an alternative con-
formation for the S atom of Cys115 (data not shown). Ca3 may be adventitiously bound, since 20 mM Ca2
Structure
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Figure 2. Overall Structure of the Complex between the Aggrecan CLD and FnIII Repeats 3–5 of Tenascin-R, TN3–5
A consistent coloring scheme is used throughout for the different domains. Surfaces, cartoon elements, and carbon atoms from domain 3
are colored beige, those in domain 4 are colored cyan, and those in domain 5 are purple. Figures 2–4 and 7 were made using Pymol (http://
www.pymol.org).
(A) Secondary structure cartoon. The three Ca2 ions are shown as yellow spheres. The boxes marked a–c denote the interaction areas for
which detailed views are given in Figures 4A–4C.
(B) Surface representation colored by domain.
(C) Exploded “open book” view of the interaction surface. The aggrecan CLD has been rotated 90 around a horizontal axis in the plane of
the paper, TN3–5 in the opposite direction. The cyan and purple patches on the surface of the CLD represent the interaction areas with TN4
and TN5, respectively. Similarly, the maroon patches on the surface of TN3–5 represent the interaction area with the CLD.
(D) The aggrecan CLD amino acid residues mediating interaction with tenascin-R form a surface corresponding to the sulfopeptide binding
surface of P-selectin in complex with PSGL-1 (Somers et al., 2000). The interaction surface of P-selectin with the protein part of the PSGL-1
sulfoglycopeptide on is colored cyan, and the carbohydrate interaction surface is colored purple. The part of the PSGL-1 peptide visible in
the crystal structure is shown as a ball-and-stick model. The figure is in the same orientation as the lower part of Figure 2C, showing the
interaction surface of tenascin-R on aggrecan.
was used in the experiments. This may also be the case face area is buried in the interface, 941 A˚2 on tenascin-R
for the aggrecan CLD, as we have used 150 mM Ca2. and 876 A˚2 on aggrecan. The CLD loops oriented toward
Ca3 does not appear to be essential for structuring loops TN3–5 form a relatively flat region, and there is shape
L1 and L4. complementarity of 0.65 (Lawrence and Colman, 1993)
between the two molecules, similar to the value for anti-
body-antigen complexes. The contact area is free ofThe Complex
carbohydrate, consistent with interaction studies show-The aggrecan CLD forms a 1:1 complex with TN3–5
ing that the interaction between recombinant aggrecan(Figure 2), making extensive contacts to the four-
CLD and tenascin-R TN3–5, with a KD of 12 nM, is inde-stranded face of TN4 and limited contact to TN5,
pendent of glycosylation, as the tenascin fragment iswhereas it makes no contact to TN3. This is consistent
bacterially expressed (Aspberg et al., 1997). Remarkablywith affinity studies using ligand-blotting assays, which
for such a tight, strictly Ca2-dependent interaction,showed weak binding of the CLD to TN3–4 but stronger
none of the Ca2 ions are coordinated by a residue onbinding to TN4–5 and TN3–5 (Aspberg et al., 1997). The
tenascin-R. In fact, no atom in tenascin-R is closer thanCLD buries most of its upper surface in the interaction
6.0 A˚ to Ca2. The two other ions are even further from(Figure 2C). Strands 6 and 7 are buried, as is the
TN3–5, on the far side of loop L4. Thus, rather thanextended loop L4 (Weis et al., 1991) structured by the
Ca2 ions. A total of 1917 A˚2 of solvent-accessible sur- binding carbohydrate or directly to tenascin-R, the Ca2
Structure of an Aggrecan CLD-Tenascin-R Complex
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between the molecules near Ca2. However, superposi-Table 2. Summary of Buried Areas and Tilt and Twist Angles at
tion of the coordinates of MBP in complex with mannoseInterfaces between FnIII Domains in Published Structures
(Ng et al., 2002) on those of the CLD show that the pocket
Buried Linker
cannot accommodate even a single sugar moiety. InDomains Area (A˚2) Sequence Tilt () Twist ()
addition, there is no path for access of the remainder
TN3–4 487 EIDAP 35 147 of a carbohydrate chain to the pocket.
TN4–5 652 ELDSP 40 115
The division of the interacting surface residues intoFN7–8 610 AVPPP 50 105
polar and nonpolar is fairly even, 60%/40%, respec-FN8–9 650 GLDSP 48 157
tively, for tenascin-R and 55%/45% for aggrecan. TheFN9–10 340 VSDVP 23 38
FN12–13 450 LENVSPP 62 38 interaction area can be divided into three patches (Fig-
FN13–14 660 AIDAP 51 147 ures 4A–4C). Close to Ca2, the surfaces are mainly hy-
drophobic. Of particular importance are two consecu-TN: present structure; FN7–10: Leahy et al. (1996), PDB code 1FNF;
FN12–14: Sharma et al. (1999), PDB code 1FNH. The buried areas tive Phe residues, 92 and 93, found in loop L4 of the
were calculated using GRASP, and the tilt and twist angles were CLD. These lock one edge of the interaction area by
calculated using the program mod2 kindly supplied by Prof. Bruno binding to a hydrophobic pocket formed by Val127,
Kieffer. The linker sequence between the respective domains is
Thr179, Tyr136, Gly165, and Pro177 from TN4 (Figuregiven, and the conserved Asp and its preceding hydrophobic resi-
4A). Phe92 and Phe93 have previously been recognizeddue are underlined where conserved. The pairs of domains with
as typical for the lectican CLDs (Brissett and Perkins,similar twist angles discussed in the text are indicated in boldface.
1998). Phe92 is structurally homologous to the residue,
often aromatic, that makes an apolar interaction with
the face of the bound carbohydrate in several CLD struc-ions function as an integral part of the structure of their
tures, e.g., His189 in MBP. It may have a similar functioncoordinating loops, ordering these such that they make
specific interactions to TN4–5. There is a small pocket if and when the lectican CLDs bind carbohydrate. How-
Figure 3. The Aggrecan CLD Fold, Comparison to Other CLDs, and Ca2 Binding
(A) The aggrecan CLD. The cartoon elements are colored from blue at the N terminus to red at the C terminus. The disulfide bridges are
highlighted, and the three Ca2 ions are shown as yellow spheres. The same coloring scheme is used in (B) and (C).
(B) A typical glycan binding CLD from mannose binding protein (Weis et al., 1992) in complex with an asparaginyl-mannose oligosaccharide,
shown in ball-and-stick representation.
(C) The long-form CLD from asialoglycoprotein receptor (Meier et al., 2000).
(D) A stereoview of Ca2 coordination in the aggrecan CLD. Water molecules are drawn as solid crosses.
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Figure 4. Details of the Interactions between
the Aggrecan CLD and TN3–5
Important interacting side chains are shown
as ball-and-stick, and the central hydrogen
bonds are highlighted. The color scheme is
as described in the legend to Figure 2.
(A) Molecular interactions of the hydrophobic
patch on loop L4 of the aggrecan CLD. The
view is approximately the same as in Fig-
ure 2A.
(B) Interactions involving the CC
 loop in TN4.
The view is approximately as in (A).
(C) Interactions of the TN4–5 linker region and
the FG loop on TN5. The molecule has been
rotated by approximately 180 around a verti-
cal axis to make the interactions clearer; i.e.,
the view is from the back of the molecule as
seen in Figure 2A.
ever, the equivalent of Phe93 in other CLDs is most volved in this H bonding network are located in loops:
Arg21 in the 2-1 loop, Gln118 in the 7-8 loop, andoften Gly or a polar residue (Brissett and Perkins, 1998).
Thus, the presence of Phe here is a signature of the Asp56 in the 2-4 loop.
lectican CLDs. Since the conformation of the sur-
rounding loop is locked by the Ca2 ions, Phe92 and Electron Microscopy of Full-Length Aggrecan
and Tenascin-RPhe93 will be exposed in solution, giving the loop a high
affinity for the hydrophobic pocket on TN4. The interaction between the aggrecan lectin domain and
the fibronectin type III repeats was confirmed by elec-In the middle of the interaction area, the tip of the CC

loop of TN4 makes a type I -turn, projecting the side tron microscopy of complexes between native aggrecan
and tenascins-R and -C (Figure 5). Mica sandwichchain of Leu131 into a hydrophobic pocket formed by
Val101, Tyr117, and Leu119 of the CLD (Figure 4B). In squeezing and rotary shadowing visualized the ability of
both tenascins to act as crosslinkers between differentthe turn, the carbonyl group of Leu131 makes a H bond
to N2 of Asn111 in the CLD, one of the ligands of Ca2. aggrecan-hyaluronan complexes. The C-terminal ends
of aggrecan monomers were frequently found associ-This is the only direct interaction of TN3–5 to any of the
Ca2 ligands. On the side of TN4 distant from Ca2, the ated with the outer extremities of the arms of both tenas-
cins (Figure 5, arrowheads). Association of the tenascinsinteraction is anchored by two salt bridges from Glu161
in TN4 to Arg21 in the CLD (data not shown). with the central filament consisting of hyaluronan, the
aggrecan G1 domain, and link protein was not observed.A complex network of H bonds at the TN4–5 junction
makes up the final cluster of interactions with the CLD
(Figure 4C). The network involves Arg183, the last resi- Discussion
due of TN4, at the end of strand G, as well as Glu161
in F and Gln261 in the FG loop of TN5 (Figure 4C). Evidence for In Vivo Hyaluronan-Lectican-
Tenascin NetworksGln261 appears to have a central role, as it locks the
conformation of the TN4–5 linker by H bonds to the The crystal structure and electron microscopy results
presented here provide detailed evidence for the modelArg183 side chain and to the main chain carbonyl of
residue 184 in the linker. This positions Arg183 to make presented in Figure 1C, where lectican G3 domain li-
gands such as the tenascins crosslink lectican-hyal-a salt bridge to Asp56 in the 2-4 loop of the CLD.
Finally, the FG loop of TN5 is thus oriented such that uronan complexes in vivo, thereby organizing the na-
scent extracellular matrix. Similar electron microscopyArg260 embraces the outer edge of the CLD, locked in
place by H bonds from the two last carbonyl groups results have been presented for fibulin-2 (Olin et al.,
2001).(Asn53 and Ala54) of 2. Trp104 in the 6-7 loop of
the CLD packs into a hydrophobic pocket formed by
residues of the FG loop of TN5. This interaction cluster Carbohydrate-Independent Interactions
of a Ca2 Binding CLDis completed by hydrogen bonds between Asn181 in
G and the main chain carbonyl and amide groups of The CTLD is a structural module found in many different
protein families with a variety of functions in, e.g., de-residue 118 in the CLD. All side chains of the CLD in-
Structure of an Aggrecan CLD-Tenascin-R Complex
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Figure 5. Tenascin-R and -C Molecules Cross-
link Aggrecan-Hyaluronan Complexes
Native link-stabilized aggrecan-hyaluronan
complexes form networks with tenascin-C (A)
and tenascin-R (B) as seen on electron micro-
graphs after mica sandwich squeezing/rotary
shadowing. The scale bar represents 100 nm.
The right-hand panels show selected ag-
gregates in a pseudocolor representation.
The individual aggrecan molecules and the
G3 domains were identified based on the
expected structures from previous work us-
ing EM and antibody labeling (Olin et al.,
2001), as are the tenascin-R and -C molecules
(Pesheva et al., 1989; Vaughan et al., 1987).
Individual aggrecan-hyaluronan complexes
(blue) are crosslinked by tenascin-C (red
hexabrachion structures in the upper panel)
or tenascin-R (red tribrachion structures in
the lower panel). To orient the viewer, the G1
and G3 domains of a single aggrecan mole-
cule are labeled. C-terminal C-type lectin do-
mains of aggrecan closely associated with the outer domains of the tenascins are indicated by arrowheads. The G1 domains form smaller
clusters than those customarily seen in similar electron micrographs due to partial hyaluronan digestion by chondroitinase.
fense against foreign agents, endocytosis, blood coagu- Interestingly, all lectican CLDs also bind tenascin-C at
the corresponding site, although brevican binds withlation, and leukocyte transmigration in inflammation
(Drickamer, 1999; Kogelberg and Feizi, 2001). The CTLD rather low affinity (Day et al., 2004; Rauch et al., 1997).
Unlike tenascin-R, which is only expressed in the CNS,superfamily includes the Ca2 binding, carbohydrate
recognizing C-type lectin (CLD) domains, as well as tenascin-C is widely expressed also in other tissues, as
are aggrecan, which is expressed in cartilage, in theother domains, found, e.g., in immune system receptors,
that share the same overall fold as Ca2 binding CLDs notochord (Domowicz et al., 1995), and in developing
heart (Zanin et al., 1999), and versican, which is widelybut lack the large loop that coordinates the Ca2 ions.
Some non-Ca2 binding CTLDs have carbohydrate li- expressed both in the adult (Bode-Lesniewska et al.,
1996) and during development, e.g., in precartilaginousgands, but many mediate direct protein-protein interac-
tions independent of Ca2. mesenchyma (Bignami et al., 1993) and heart (Hender-
son and Copp, 1998). Could the present structure thusAlthough lectican CLDs can also bind simple carbohy-
drates (Halberg et al., 1988; Saleque et al., 1993) and be a general model for the widespread extracellular ma-
trix interactions between different lecticans and tenas-sulfated glycolipids (Miura et al., 1999) in a Ca2-depen-
dent manner, a more well-defined role is in binding cins in diverse tissues?
Figure 6 shows sequence alignments of the lecticanmultimeric ECM ligands using direct protein-protein in-
teractions, with no involvement of carbohydrate (Asp- CLDs and of tenascin-R and -C. Of the 24 aggrecan
CLD residues identified by the Protein-Protein Interac-berg et al., 1997). The crystal structure confirms this:
the highly complementary surfaces of the two protein tion Server (Jones and Thornton, 1996) as being in the
interface region (with atoms closer than 4 A˚), 8 are com-moieties in the complex preclude classical CLD carbo-
hydrate interactions, as both Ca2 and carbohydrate pletely conserved in the lectican CLDs, 8 are conserva-
tively substituted, and 4 make main chain interactionsbinding amino acid residues are shielded from the sur-
face. Previous structural studies of CLD interactions only or have side chains pointing away from the interface
(Figure 6A). This leaves only four residues with noncon-have shown these to depend on coordination of Ca2
by hydroxyl groups of the carbohydrate ligands. We servative substitutions that are intimately involved in the
interaction: Tyr57, Arg85, Trp104, and Asn111. Of these,therefore imagined that Asp, Asn, Glu, or Gln residues
in the TN3–5 might form part of the aggrecan CLD Ca2 Asn111 is the most interesting. It is completely con-
served except in brevican, where it is substituted bycoordination sphere, replacing the carbohydrate oxy-
gens. The structure clearly shows that this is not the serine. This is one of the ligands to Ca2 and also makes
a H bond which helps lock the CC
 loop of TN4 in placecase. The Ca2 ions are essential to structure the binding
loops of the CLD, but it is the characteristic surface on the CLD (Figure 4B). Nevertheless, brevican makes
residues rather than intrinsic properties of the Ca2bind- a tight in vitro interaction with tenascin-R (KD  1.1 nM)
ing that result in the observed nanomolar affinity. (Aspberg et al., 1997). Given the complete conservation
of the other Ca2 ligands, it is unlikely that brevican does
not bind Ca2, though it remains to be seen whether SerA General Model for Lectican-
is a Ca2 ligand. The other nonconserved residues areTenascin Interactions
more easily accommodated: Trp104 is substituted byAll four lecticans are expressed in the CNS and can thus
alanine in brevican; Tyr57 packs in a semihydrophobicinteract with tenascin-R (Milev et al., 1998; Popp et al.,
pocket containing H bonding groups that could house2003). Biochemical studies confirm that all lectican
CLDs bind tenascin-R in vitro (Aspberg et al., 1997). the Asn substitution in neurocan; and Arg85 contacts
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Figure 6. Sequence Alignments of Lectican CLDs and Tenascin FnIII Repeats 4–5 from Rat and Human
Sequence alignments of lectican CLDs and tenascin FnIII repeats 4–5 from rat and human (representative of the other sequences in the Swiss-
Prot database). In both (A) and (B), residues in the interaction area of the present complex are marked with blue triangles. The secondary
structure and numbering from the present structure are drawn above the sequence alignments. The sequence alignment was made using
ESPRIPT (Gouet et al., 1999).
(A) The lectican CLDs. The residues coordinating the Ca2 ions are highlighted with green triangles (Ca2), black triangles (Ca1), and red
triangles (Ca3).
(B) Tenascin-R and tenascin-C, FnIII repeats 4–5. Residues in the interaction surface with the aggrecan CLD are marked with blue triangles.
Residues shown in Figure 4A are highlighted with circles, Leu131 (see Figure 4B) is highlighted with a star, and the residues in Figure 4C are
highlighted with boxes.
the tip of the CC
 loop in TN4, only 5 A˚ from Asn111. and -C interactions. Additionally, we predict that direct
coordination of Ca2 by tenascin will not be a feature ofAn Asn substitution at this position in brevican could
provide an extra H bond to the carbonyl of Ala132 in any of the other complexes.
Using rotary shadowing electron microscopy, we di-TN4, which might compensate the loss of interaction
between Leu131 in tenascin-R and Asn111 in brevican. rectly observed tenascin-mediated crosslinking of na-
tive link-stabilized aggrecan-hyaluronan complexes, forSequence conservation in tenascin-R and -C is even
higher: 13 completely conserved, 5 conservative substi- the first time in vitro. The C-terminal lectin domain ends
of aggrecan monomers were found associated with thetutions, 3 main chain or pointing away, and only 3 non-
conservative substitutions (Figure 4B). This, taken to- outer portions of the tenascin-R and -C molecules, in
good agreement with previous biochemical data. Thisgether with the fact that the lectican CLDs compete for
the same binding site on tenascin-R (Aspberg et al., confirms that the interaction of the domains seen in the
crystal structure is representative of the interactions of1997), argues strongly that the present structure is in-
deed a general model for all lectican CLD-tenascin-R the full-length molecules.
Structure of an Aggrecan CLD-Tenascin-R Complex
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Figure 7. A Comparison of the Linker Re-
gions between FnIII Repeats in Fibronectin
and Tenascin-R
(A) Comparison of the linker between FN13
and 14 in fibronectin (Sharma et al., 1999) and
the linker between TN3 and 4 in the present
structure. FN13–14 is colored uniformly yel-
low. TN3 is colored beige, and the linker and
TN4 are colored cyan. The molecules are su-
perimposed using the coordinates of TN3 and
FN13; i.e., the following domains are free to
rotate.
(B) A comparison of the FN13–14 linker in
fibronectin with the one between TN4 and 5
in the present structure. TN4 is colored cyan
and TN5 is colored blue. The structures are
superimposed using the coordinates of TN4
and FN13.
Role of the xφDφP Sequence in the Linker CLD must bind both to sulfated tyrosine residues in the
PSGL-1 N-terminal peptide and to a Sialyl LewisX glycanRegions of TN3–5
carried on the same peptide (Pouyani and Seed, 1995;Sharma et al. (1999) highlighted the importance of the
Sako et al., 1995; Wilkins et al., 1995). In the structurespecific sequence of the linker region between repeats
of P-selectin in complex with the N-terminal glycosulfo-13 and 14 of human fibronectin, which is 182AIDAP.
peptide of PSGL-1, the glycan binding site (includingAsp184 (underlined) pins down the BC loop from FN14
Ca2) and the peptide binding site on the P-selectin CLD(which contains a sequence critical for integrin41 bind-
were adjacent (Somers et al., 2000). Interestingly, theing) through a double H bond to main chain amide
protein binding surface of P-selectin corresponds to agroups (Figure 7A). The preceding Ile183 (also under-
subset of the surface mediating tenascin-R interactionlined above) packs into a small hydrophobic pocket. A
in the aggrecan CLD (Figure 2D). This common proteinsimilar interaction occurs between FN8 and FN9 in the
interaction surface mainly consists of loops that areFN7–10 crystal structure (Leahy et al., 1996), where the
subject to considerable variation in different CLDs. Thelinker sequence is GLDSP, and it was suggested that
Ca2 binding CLD family has many members (Ebner etthe interaction might be general in the several interfaces
al., 2003), and it is commonly assumed that the purposebetween FnIII repeats having this linker sequence. Inter-
of the Ca2 binding face of the molecule is always toestingly, homologous sequences are found both be-
recognize carbohydrates. However, the overlapping sur-tween TN3–4 and TN4–5, namely 93EIDAP and 185ELDSP.
face area used for protein binding in the aggrecan CLDAt the TN3–4 interface, Ile94 and Asp95 behave very
and in P-selectin suggests that protein-protein interac-much as their homologs in the FN8–9 and FN13–14 link-
tions of Ca2 binding CLDs that use the surface adjacenters (Figure 7A), reflected in very similar tilt and twist
to or overlapping with the carbohydrate binding site mayangles for all three (152  5; see Table 2). However
be more common than previously appreciated. Ligand
the ELDSP sequence between TN4–5 has a different
binding may involve protein alone as in the lecticans,
geometry, in which Asp187 is projected out of the inter- or it may occur in combination with glycan ligands as
face, making a salt bridge to Arg190. This is reflected in P-selectin.
in a twist angle differing by 37 from the average value
for the other interfaces (Figure 7B; Table 2). This is most Experimental Procedures
likely due to the predominance of interactions with ag-
Production of Recombinant Proteins and Preparationgrecan in this area. The different twist angle is more
of Protein Complexeslikely to be a natural property of the TN4–5 interface
The construction of a His-tagged aggrecan CLD mammalian expres-
than to be induced by the interactions with aggrecan, sion pCEP4 plasmid and production of the recombinant protein
due to the intricate H bonding interactions between do- has previously been described (Aspberg et al., 1997, 1999). The
production of the recombinant tenascin-R fragment constituted bymains 4 and 5 (Figure 4C). A major factor in selection
FnIII repeats 3–5 (TN3–5) as a glutathione S-transferase (GST) fusionof this twist angle is the orientation of the FG loop of
protein has been described (Xiao et al., 1996). The TN3–5 fusionTN5 such that Arg260 can embrace the outer edge of
protein was expressed in Escherichia coli strain TG-1, isolated on
the aggrecan CLD (Figure 4C). Thus, the conformation glutathione-Sepharose (Amersham Biosciences), released from its
of the xφDφP linker (whereφ is a hydrophobic residue) fusion partner by thrombin digestion, and further purified on a Mono
Q column as previously described (Aspberg et al., 1997).frequently seen in FnIII linker regions may sometimes
The recombinant aggrecan CLD and TN3–5 were incubated to-result in a broadly similar orientation of two consecutive
gether in equimolar amounts (1:2 mg/ml) after dialysis into 20 mMFnIII domains, but only in the absence of more important
HEPES (pH 7.5) and 4 mM CaCl2. The complexes were concentrated
external factors driving another relative orientation. to 3 mg/ml of total protein. The formation of complexes, but not
aggregates, was monitored by negative staining electron mi-
croscopy.Comparison with P-Selectin Reveals
an Overlapping Protein Binding Surface Crystallization
For high-affinity interaction between P-selectin and the Initial crystallization conditions were found using the Crystal Screen
I  II kits (Hampton Research, Aliso Viejo, CA) using 2–3 l sittingP-selectin glycoprotein ligand-1 (PSGL-1) the P-selectin
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